Vijaya Diagnostic Share Price: 35.6% CAGR in 3 Years as This Relatively New Lab Chain Takes On Dr Lal PathLabs, Metropolis and Thyrocare
- November 4, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Vijaya Diagnostic Share Price: 35.6% CAGR in 3 Years as This Relatively New Lab Chain Takes On Dr Lal PathLabs, Metropolis and Thyrocare
Vijaya Diagnostic previous close Rs 1,447.10. 3-year CAGR 35.6%. Up 2.5x since 3 Nov 2023. ROE 18.07%. Market cap Rs 14,914 crore.
Quick Answer
The Vijaya Diagnostic share price closed at Rs 1,447.10 on 3 November 2026, a compounded annual return of 35.6% over three years. That compares with Thyrocare at 38.1%, Metropolis Healthcare at 15.6% and Dr Lal PathLabs at 14.1%. The company has a market cap of Rs 14,914 crore and a P/E of 79.56 against an industry P/E of 62.82.
The Vijaya Diagnostic share price has more than doubled in three years, a performance that puts a regional diagnostics chain in the same conversation as the best-known names in Indian pathology. Vijaya Diagnostic Centre, based in Hyderabad, listed in 2021 and has expanded steadily beyond its home markets.
We compare the three-year CAGR of Vijaya with Thyrocare, Metropolis Healthcare and Dr Lal PathLabs, and set it against market cap, valuation and return on equity. Prices are adjusted for corporate actions so the comparison is like for like.
Click Here – Get Free Investment Predictions
How Much Has the Vijaya Diagnostic Share Price Returned in 3 Years?
The Vijaya Diagnostic stock closed at Rs 579.85 on 3 November 2023 and at Rs 1,447.10 on 3 November 2026. Rs 1 lakh invested three years ago would have grown to about Rs 2.50 lakh, which is a CAGR of 35.6%. This is a price return and leaves out dividends.
CAGR condenses a bumpy three-year ride into one yearly number, which is why it is the fairest way to compare companies of different sizes. A stock such as Vijaya Diagnostic can look spectacular on a chart and still have earned a modest yearly return, so the compounded figure keeps the comparison honest.
The Vijaya Diagnostic share price has benefited from rising health awareness, more preventive testing and the shift of diagnostics from small neighbourhood labs to organised chains.
Vijaya Diagnostic vs Thyrocare, Metropolis Healthcare and Dr Lal PathLabs: 3-Year CAGR Compared
The table ranks the companies by three-year CAGR. Prices on 3 November 2023 are adjusted for splits and bonuses, and the latest figures are the previous close on 3 November 2026.
| Company | Close on 3 Nov 2023 | Previous close (3 Nov 2026) | Price multiple | 3-year CAGR |
|---|---|---|---|---|
| Thyrocare | Rs 183.17 | Rs 482.90 | 2.6x | 38.1% |
| Vijaya Diagnostic Centre | Rs 579.85 | Rs 1,447.10 | 2.5x | 35.6% |
| Metropolis Healthcare | Rs 368.11 | Rs 568.70 | 1.5x | 15.6% |
| Dr Lal PathLabs | Rs 1,297.33 | Rs 1,925.70 | 1.5x | 14.1% |
The Vijaya Diagnostic stock ranks second of the four at 35.6%. It sits ahead of Metropolis Healthcare (15.6%) and Dr Lal PathLabs (14.1%). The company ahead is Thyrocare (38.1%). Thyrocare edged ahead of Vijaya, with the two clearly in front of Metropolis and Dr Lal PathLabs. The diagnostics group as a whole has performed well, with every company compounding at double-digit rates.
Look at the Vijaya Diagnostic share price alongside the peers as a snapshot of the last three years. It describes what happened, and valuation and earnings will decide what happens next.
Valuation and Quality Compared
| Company | Market cap | P/E | Industry P/E | ROE | Debt to equity |
|---|---|---|---|---|---|
| Dr Lal PathLabs | Rs 32,373 crore | 59.25 | 62.82 | 20.13% | 0.08 |
| Vijaya Diagnostic Centre | Rs 14,914 crore | 79.56 | 62.82 | 18.07% | 0.44 |
| Metropolis Healthcare | Rs 11,799 crore | 58.15 | 62.82 | 12.56% | 0.15 |
| Thyrocare | Rs 7,679 crore | 53.61 | 62.82 | 31.66% | 0.10 |
By market cap, Dr Lal PathLabs is the largest of the group at Rs 32,373 crore, while the Vijaya Diagnostic stock stands at Rs 14,914 crore, about 46% of that size. On earnings, Vijaya Diagnostic shares trade at a P/E of 79.56 against an industry P/E of 62.82, a premium of about 27%, which signals that the market expects faster earnings growth. Peer multiples are Thyrocare at 53.61, Metropolis Healthcare at 58.15 and Dr Lal PathLabs at 59.25.
Return on equity is 18.07% for the Vijaya Diagnostic stock, which ranks third among the four, and debt to equity stands at 0.44. Trailing EPS is Rs 18.20. Diagnostics trade at high multiples across the sector because the business is asset-light, cash generative and grows with health spending, which is why even the industry average sits above 60.
What Is Driving the Vijaya Diagnostic Stock?
Vijaya Diagnostic Centre runs a network of pathology labs, radiology centres and collection points, with a strong presence in Hyderabad and the south and a growing footprint in other states. It offers a combined pathology and imaging service under one roof, which is relatively uncommon among organised chains.
The organised segment of diagnostics is still a minority of a market dominated by small labs. As patients prefer accredited quality and doctors rely more on test data, volumes move toward larger chains. Vijaya adds new centres, builds scale in each city, and improves the revenue per patient.
Following the Vijaya Diagnostic share price means tracking centre additions, revenue per test, the contribution of radiology, and the pace of entry into new cities.
How the Established Players Stack Up
Thyrocare is known for high-volume preventive health packages. It compounded at 38.1% a year and earns the highest ROE in the group at 31.66%, with a dividend yield of 2.90%.
Dr Lal PathLabs is one of the largest listed pathology chains. It compounded at 14.1% a year on a market cap of Rs 32,373 crore and an ROE of 20.13%.
Metropolis Healthcare is a well-established pathology brand with a national footprint. It compounded at 15.6% a year and trades at a P/E of 58.15.
What Should Investors Track Next?
Three things to follow on the Vijaya Diagnostic share price. First, centre and volume growth in newer markets. Second, margins as radiology grows, since imaging has a different cost structure from pathology. Third, regulatory or pricing changes in healthcare services.
At a P/E of 79.56 against an industry average of 62.82, the market has built expansion into the price. Smaller regional chains can also be more volatile than the national leaders.
Check the Univest Screener for live fundamentals of healthcare stocks
How to Compare Diagnostics Stocks Yourself
You can repeat this exercise for any pair of stocks, including the Vijaya Diagnostic stock against its peers. Note the adjusted closing price on the base date, take the latest close, divide one by the other, raise the result to the power of one third and subtract one. Then place the CAGR next to market cap, P/E against the industry P/E, ROE and debt to equity. Benchmark the result against the Nifty 50 as well, so you know whether the stock beat the broader market.
A stock that scores well on growth but weakly on quality, or the reverse, deserves closer study before it enters a portfolio. When tracking the Vijaya Diagnostic share price, the same four checks give a more complete picture than price alone.
Download the Univest iOS App or Univest Android App to track the Vijaya Diagnostic share price and compare diagnostics stocks live.
A Regional Chain With National Ambitions
The Vijaya Diagnostic share price compounded at 35.6% a year over three years, ahead of Dr Lal PathLabs at 14.1% and Metropolis at 15.6%, and just behind Thyrocare at 38.1%.
The group shares strong industry tailwinds, so the choice among them often comes down to valuation, growth pace and the quality of returns. Vijaya brings combined pathology and radiology and room to expand into new cities.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the Vijaya Diagnostic share price today?
Ans. Vijaya Diagnostic Centre closed at Rs 1,447.10 on 3 November 2026, according to NSE data. It has a market cap of Rs 14,914 crore and a P/E of 79.56. Check live quotes before acting, as prices change every trading day.
What is the 3-year CAGR of the Vijaya Diagnostic stock?
Ans. Vijaya Diagnostic Centre delivered a price CAGR of 35.6% over three years, moving from Rs 579.85 on 3 November 2023 to Rs 1,447.10 on 3 November 2026. The figure excludes dividends and uses adjusted closing prices.
Is Vijaya Diagnostic better than Dr Lal PathLabs?
Ans. The Vijaya Diagnostic stock delivered a higher three-year CAGR at 35.6% than Dr Lal PathLabs at 14.1%. Dr Lal is larger by market cap and trades at a P/E of 59.25 against 79.56 for Vijaya. Better depends on your view of growth and price.
What does Vijaya Diagnostic Centre do?
Ans. Vijaya Diagnostic Centre is a Hyderabad-based diagnostics chain offering pathology and radiology services through labs, imaging centres and collection points across South India and other states.
Is the Vijaya Diagnostic stock debt free?
Ans. The debt to equity ratio of the Vijaya Diagnostic stock is 0.44 and its return on equity is 18.07%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.
Is Vijaya Diagnostic expensive compared with the industry?
Ans. Vijaya Diagnostic trades at a P/E of 79.56 against an industry P/E of 62.82. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.
Which diagnostics stock gave the highest return in 3 years?
Ans. Among the companies compared here, Thyrocare delivered the highest three-year CAGR at 38.1%, followed by Vijaya Diagnostic Centre at 35.6%. Past returns do not guarantee future performance.
How do I calculate CAGR for a stock?
Ans. Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.